MRNA - Moderna, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
MRNA price evolution
MRNA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2478 | $2051 | $2907 | |
| Short term investments | $6010 | $6472 | $5697 | |
| Net receivables | $1836 | $163 | $137 | $892 |
| Inventory | $412 | $399 | $295 | $202 |
| Total current assets | $9666 | $9661 | $9600 | $10325 |
| Long term investments | $2326 | $3638 | $4677 | |
| Property, plant & equipment | $3165 | $2971 | $2760 | $2658 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6019 | $7129 | $8101 | |
| Total investments | $8336 | $10110 | $10374 | |
| Total assets | $15803 | $15680 | $16729 | $18426 |
| Current liabilities | ||||
| Accounts payable | $373 | $279 | $183 | $520 |
| Deferred revenue | $797 | $617 | $651 | |
| Short long term debt | ||||
| Total current liabilities | $2201 | $2363 | $2380 | $3015 |
| Long term debt | $625 | $1244 | $1212 | $1218 |
| Total noncurrent liabilities | $1605 | $1532 | $1557 | |
| Total debt | $1244 | $1212 | $1218 | |
| Total liabilities | $3876 | $3968 | $3912 | $4572 |
| Shareholders' equity | ||||
| Retained earnings | $11165 | $11152 | $12431 | $13606 |
| Other shareholder equity | -$1.04 | -$71 | -$101 | -$123 |
| Total shareholder equity | $11712 | $12817 | $13854 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2907 | $3205 | $6848 | $2624.88 |
| Short term investments | $5697 | $6697 | $3879 | $1983.76 |
| Net receivables | $892 | $1385 | $3175 | $1390.56 |
| Inventory | $202 | $949 | $1441 | $46.53 |
| Total current assets | $10325 | $13431 | $16071 | $6297.88 |
| Long term investments | $4677 | $8318 | $6855 | $649.9 |
| Property, plant & equipment | $2658 | $2139 | $1383 | $387.09 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $8101 | $12427 | $8598 | $1038.87 |
| Total investments | $10374 | $15015 | $10734 | $2633.66 |
| Total assets | $18426 | $25858 | $24669 | $7336.75 |
| Current liabilities | ||||
| Accounts payable | $520 | $487 | $302 | $18.36 |
| Deferred revenue | $651 | $2711 | $6868 | $4044.61 |
| Short long term debt | ||||
| Total current liabilities | $3015 | $4923 | $9128 | $4388.81 |
| Long term debt | $1218 | $912 | $705 | $207.29 |
| Total noncurrent liabilities | $1557 | $1812 | $1396 | $386.57 |
| Total debt | $1218 | $1004 | $705 | $207.29 |
| Total liabilities | $4572 | $6735 | $10524 | $4775.38 |
| Shareholders' equity | ||||
| Retained earnings | $13606 | $18320 | $9958 | -$2243.52 |
| Other shareholder equity | -$123 | -$370.04 | -$24 | $3 |
| Total shareholder equity | $13854 | $19123 | $14145 | $2561.38 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $241 | $167 | $2811 | |
| Cost of revenue | $115 | $96 | $929 | |
| Gross Profit | $126 | $71 | $1882 | |
| Operating activities | ||||
| Research & development | $1221 | $1063 | $1406 | |
| Selling, general & administrative | $268 | $274 | $470 | |
| Total operating expenses | $1489 | $1337 | $1876 | |
| Operating income | -$1363 | -$1266 | $6 | |
| Income from continuing operations | ||||
| EBIT | -$1279 | -$1165 | $70 | |
| Income tax expense | $10 | -$147 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$1279 | -$1175 | $217 | |
| Income (for common shares) | -$1279 | -$1175 | $217 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6848 | $19263 | $18471 | $803.39 |
| Cost of revenue | $4693 | $5416 | $2617 | $7.93 |
| Gross Profit | $2155 | $13847 | $15854 | $795.46 |
| Operating activities | ||||
| Research & development | $4845 | $3295 | $1991 | $1370.34 |
| Selling, general & administrative | $1549 | $1132 | $567 | $188.27 |
| Total operating expenses | $6394 | $4427 | $2558 | $1558.61 |
| Operating income | -$4239 | $9420 | $13296 | -$763.14 |
| Income from continuing operations | ||||
| EBIT | -$3942 | $9575 | $13285 | -$744.51 |
| Income tax expense | $772 | $1213 | $1083 | $2.55 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$4714 | $8362 | $12202 | -$747.06 |
| Income (for common shares) | -$4714 | $8362 | $12202 | -$747.06 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1279 | -$1175 | $217 | |
| Operating activities | ||||
| Depreciation | $41 | $36 | $202 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $112 | $101 | $79 | |
| Total cash flows from operations | -$1274 | -$989 | $622 | |
| Investing activities | ||||
| Capital expenditures | -$182 | -$196 | -$220 | |
| Investments | $1831 | $314 | -$318 | |
| Total cash flows from investing | $2488 | $1649 | $118 | -$538 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $32 | $15 | $15 | |
| Net borrowings | $2 | -$1 | -$124 | |
| Total cash flows from financing | $59 | $34 | $14 | -$109 |
| Effect of exchange rate | $1 | |||
| Change in cash and equivalents | -$1281 | $409 | -$857 | -$25 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$4714 | $8362 | $12202 | -$747.06 |
| Operating activities | ||||
| Depreciation | $621 | $348 | $232 | $93.54 |
| Business acquisitions & disposals | -$85 | |||
| Stock-based compensation | $305 | $226 | $142 | $93.02 |
| Total cash flows from operations | -$3118 | $4981 | $13620 | $2026.97 |
| Investing activities | ||||
| Capital expenditures | -$707 | -$400 | -$284 | -$67.45 |
| Investments | $4998 | -$4776 | -$8239 | -$1604.48 |
| Total cash flows from investing | $4206 | -$5176 | -$8523 | -$1671.93 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$1107 | -$3264 | -$733 | $2039.41 |
| Net borrowings | -$270 | -$184 | -$140 | -$6.21 |
| Total cash flows from financing | -$1377 | -$3448 | -$873 | $2033.19 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$289 | -$3643 | $4224 | $2388.24 |
News
|
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks...
Benzinga
24 Feb 2025
|
|
Moderna: A Generational Opportunity for Investors in 2025 | Investing.com
Investing.com
19 Feb 2025
|
|
Why Moderna (MRNA) Went Up on Tuesday?
Insider Monkey · via Yahoo Finance
19 Feb 2025
|
|
Stock Market News for Feb 18, 2025
Zacks · via Yahoo Finance
19 Feb 2025
|
|
Moderna’s Shot Sales, Canceled Contract Lead to Another Loss
Bloomberg · via Yahoo Finance
14 Feb 2025
|
|
Moderna looks to pipeline to restore battered stock after quarterly loss
Market Watch
14 Feb 2025
|
|
Moderna shares rise on quarterly revenue beat despite wider-than-expected loss
Proactive Investors
14 Feb 2025
|
|
Why Are Analysts Bullish on Moderna, Inc. (MRNA) Now?
Insider Monkey · via Yahoo Finance
2 Feb 2025
|
|
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.31% By...
Investing.com
30 Jan 2025
|
|
Why Moderna (MRNA) Crashed on Wednesday?
Insider Monkey · via Yahoo Finance
30 Jan 2025
|
Fundamentals
| Market cap | $9.67B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 385.00M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.33 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.39 |
| Quick ratio | 4.20 |